A case of junctional epidermolysis bullosa intermediate with collagen XVII deficiency treated with dupilumab
AbstractInherited epidermolysis bullosa is a heterogeneous group of hereditary skin diseases characterized by skin (mucosa) fragility, which leads to blistering. Junctional epidermolysis bullosa is associated with mutations in genes expressing proteins of the dermo-epidermal junction. Dupilumab, an...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_e7d4b6bfd7e14cd2b02f4a1b7c70fea8 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Li Zhang |e author |
700 | 1 | 0 | |a Shangshang Wang |e author |
700 | 1 | 0 | |a Qinyi Chen |e author |
700 | 1 | 0 | |a Leihong Xiang |e author |
245 | 0 | 0 | |a A case of junctional epidermolysis bullosa intermediate with collagen XVII deficiency treated with dupilumab |
260 | |b Taylor & Francis Group, |c 2023-12-01T00:00:00Z. | ||
500 | |a 10.1080/09546634.2023.2253943 | ||
500 | |a 1471-1753 | ||
500 | |a 0954-6634 | ||
520 | |a AbstractInherited epidermolysis bullosa is a heterogeneous group of hereditary skin diseases characterized by skin (mucosa) fragility, which leads to blistering. Junctional epidermolysis bullosa is associated with mutations in genes expressing proteins of the dermo-epidermal junction. Dupilumab, an antibody that directly targets interleukin (IL)-4 receptor alpha, may be an effective treatment for dystrophic epidermolysis bullosa. We describe a case of junctional epidermolysis bullosa that improved with dupilumab. | ||
546 | |a EN | ||
690 | |a Junctional epidermolysis bullosa1 | ||
690 | |a dupilumab2 | ||
690 | |a treatment3 | ||
690 | |a COL17A14 | ||
690 | |a itch5 | ||
690 | |a pruritus6 | ||
690 | |a Dermatology | ||
690 | |a RL1-803 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Journal of Dermatological Treatment, Vol 34, Iss 1 (2023) | |
787 | 0 | |n https://www.tandfonline.com/doi/10.1080/09546634.2023.2253943 | |
787 | 0 | |n https://doaj.org/toc/0954-6634 | |
787 | 0 | |n https://doaj.org/toc/1471-1753 | |
856 | 4 | 1 | |u https://doaj.org/article/e7d4b6bfd7e14cd2b02f4a1b7c70fea8 |z Connect to this object online. |